PTH decreased cell apoptosis in a Flt-3L expanded population. by Flavia Q. Pirih (360515)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Overexpression of PR decreases Myc expression and activity. by Tamar Kavlashvili (849072)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Rdh10a deficient embryos have decreased expression of RA signaling responsive genes. by Enrico D’Aniello (798447)

“…<p>(A-F) ISH for <i>cyp26a1</i>, <i>hoxb5b</i>, <i>and dhrs3a</i> expression in control sibling and Rdh10a deficient embryos. …”

Cooperativity decreases with the expression level of CheA. by Stephan Eismann (835052)

NaSal increased the excitability of 5-HTergic neurons, but decreased that of GABAergic neurons in the DRN of the ChR2 transgenic mouse. by Yan Jin (143500)

“…(D) Sample traces (left panel) and group data (right panel, paired Student’s <i>t</i>-test) showing that NaSal suppressed the firing of GABAergic neurons evoked by laser light (1 s, 5.5 mW, 473 nm). (E) Sample recordings from a GABAergic neuron showing that NaSal decreased voltage responses to a series of hyperpolarizing currents (-10 to -60 pA, -10 pA/step, duration: 500 ms). …”